AP2014007606A0 - 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases - Google Patents

1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases

Info

Publication number
AP2014007606A0
AP2014007606A0 AP2014007606A AP2014007606A AP2014007606A0 AP 2014007606 A0 AP2014007606 A0 AP 2014007606A0 AP 2014007606 A AP2014007606 A AP 2014007606A AP 2014007606 A AP2014007606 A AP 2014007606A AP 2014007606 A0 AP2014007606 A0 AP 2014007606A0
Authority
AP
ARIPO
Prior art keywords
arylcarbonyl
oxy
treatment
neurodegenerative diseases
compounds useful
Prior art date
Application number
AP2014007606A
Other languages
English (en)
Inventor
Tatsuki Koike
Haruhi Ando
William John Farnaby Farnaby
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47143241&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2014007606(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AP2014007606A0 publication Critical patent/AP2014007606A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
AP2014007606A 2011-10-07 2012-10-03 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases AP2014007606A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011222741 2011-10-07
PCT/JP2012/076257 WO2013054822A1 (fr) 2011-10-07 2012-10-03 Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives

Publications (1)

Publication Number Publication Date
AP2014007606A0 true AP2014007606A0 (en) 2014-05-31

Family

ID=47143241

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007606A AP2014007606A0 (en) 2011-10-07 2012-10-03 1-Arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases

Country Status (43)

Country Link
US (11) US8648079B2 (fr)
EP (1) EP2763979B1 (fr)
JP (1) JP6117191B2 (fr)
KR (1) KR101967497B1 (fr)
CN (1) CN103842356B (fr)
AP (1) AP2014007606A0 (fr)
AR (1) AR088226A1 (fr)
AU (1) AU2012321815B2 (fr)
BR (2) BR122022001219B1 (fr)
CA (1) CA2851087C (fr)
CL (1) CL2014000806A1 (fr)
CO (1) CO6940432A2 (fr)
CR (1) CR20140151A (fr)
CY (1) CY1121549T1 (fr)
DK (1) DK2763979T3 (fr)
DO (1) DOP2014000064A (fr)
EA (1) EA025662B1 (fr)
EC (1) ECSP14013329A (fr)
ES (1) ES2716531T3 (fr)
GE (1) GEP201706608B (fr)
HR (1) HRP20190491T1 (fr)
HU (1) HUE043171T2 (fr)
IL (1) IL231678A (fr)
LT (1) LT2763979T (fr)
MA (1) MA35623B1 (fr)
ME (1) ME03372B (fr)
MX (1) MX360706B (fr)
MY (1) MY176126A (fr)
PE (1) PE20141120A1 (fr)
PH (1) PH12014500759A1 (fr)
PL (1) PL2763979T3 (fr)
PT (1) PT2763979T (fr)
RS (1) RS58470B1 (fr)
SG (1) SG2014010417A (fr)
SI (1) SI2763979T1 (fr)
SM (1) SMT201900173T1 (fr)
TN (1) TN2014000122A1 (fr)
TR (1) TR201902788T4 (fr)
TW (1) TWI582084B (fr)
UA (1) UA115133C2 (fr)
UY (1) UY34365A (fr)
WO (1) WO2013054822A1 (fr)
ZA (1) ZA201402424B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648079B2 (en) * 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds
WO2014061676A1 (fr) 2012-10-16 2014-04-24 武田薬品工業株式会社 Composé hétérocyclique
EA029056B1 (ru) 2012-12-11 2018-02-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
FI3932932T3 (fi) 2013-03-13 2025-10-15 Sage Therapeutics Inc Neuroaktiivisia steroideja ja niiden käyttömenetelmiä
WO2014163161A1 (fr) 2013-04-04 2014-10-09 武田薬品工業株式会社 Composé hétérocyclique
US9624184B2 (en) 2013-04-04 2017-04-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015190613A1 (fr) 2014-06-09 2015-12-17 Takeda Pharmaceutical Company Limited Composés radiomarqués
JP6628745B2 (ja) 2014-06-18 2020-01-15 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびその使用方法
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
PT3319611T (pt) 2015-07-06 2021-04-22 Sage Therapeutics Inc Oxisteróis e métodos de utilização dos mesmos
DK3812392T3 (da) 2015-07-06 2025-07-21 Sage Therapeutics Inc Oxysteroler og fremgangsmåder til anvendelse deraf
JP6807322B2 (ja) * 2015-10-16 2021-01-06 武田薬品工業株式会社 複素環化合物の製造方法
GB201604029D0 (en) * 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
ES2921010T3 (es) 2016-04-01 2022-08-16 Sage Therapeutics Inc Oxisteroles y procedimientos de uso de los mismos
WO2017193046A1 (fr) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxystérols et méthodes d'utilisation associées
WO2017195894A1 (fr) * 2016-05-13 2017-11-16 日産化学工業株式会社 Procédé de production d'un composé de type 2-acétylpyridine
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
GB201617758D0 (en) * 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
US11285139B2 (en) 2017-08-31 2022-03-29 Takeda Pharmaceutical Company Limited Treatment of CNS conditions
WO2020027344A1 (fr) 2018-08-03 2020-02-06 Takeda Pharmaceutical Company Limited Inhibiteurs de ch24h pour utilisation mdd
JP7443255B2 (ja) * 2018-09-20 2024-03-05 武田薬品工業株式会社 疼痛使用のためのｃｈ２４ｈ阻害剤
TWI855081B (zh) * 2019-05-24 2024-09-11 美商賽吉醫療公司 化合物、組合物及使用方法
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
IL303170A (en) * 2020-11-25 2023-07-01 Sage Therapeutics Inc 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
EP4351588A1 (fr) 2021-06-11 2024-04-17 Sage Therapeutics, Inc. Stéroïde neuroactif pour le traitement de la maladie d'alzheimer
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases
CN116444477B (zh) * 2023-04-04 2026-01-02 宁波九胜创新医药科技有限公司 一种溴代胡椒环羧酸的制备方法及其用途
CN122249207A (zh) * 2023-07-18 2026-06-19 总医院公司 用于治疗神经变性的蛋白降解靶向嵌合体
WO2025126159A1 (fr) 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited Procédé de traitement d'une maladie neurologique chez un utilisateur de drogue récréative
WO2025257799A1 (fr) 2024-06-14 2025-12-18 Takeda Pharmaceutical Company Limited Méthodes de traitement du syndrome de dravet

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (fr) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de substances amyloides
EP1586584A1 (fr) 1996-08-27 2005-10-19 Praecis Pharmaceuticals Incorporated Modulateurs de l'agrégation de peptides beta-amyloides, comprenant des D-aminoacides
EP1194449B1 (fr) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibiteurs de memapsine 2 et son utilisation
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
PT1285651E (pt) 2000-04-28 2010-10-21 Takeda Pharmaceutical Antagonistas da hormona concentradora da melanina
EP1283199A4 (fr) 2000-05-16 2003-12-17 Takeda Chemical Industries Ltd Antagoniste de l'hormone de concentration de la melanine
WO2002064558A2 (fr) 2001-02-14 2002-08-22 Sankyo Company, Limited Derives d'oxazole, leur preparation et leur utilisation comme inhibiteurs de cytokines
JP2004532234A (ja) 2001-04-27 2004-10-21 バーテックス　ファーマシューティカルズ　インコーポレイテッド トリアゾール由来キナーゼインヒビターおよびその使用
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
AU2003288231A1 (en) 2002-12-13 2004-07-09 Bayer Healthcare Ag Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
DOP2005000039A (es) 2004-03-26 2005-10-31 Aventis Pharma Inc Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
US20060167044A1 (en) 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
JPWO2006137465A1 (ja) 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
DE602006020482D1 (de) 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
TW200738261A (en) 2005-12-20 2007-10-16 Bristol Myers Squibb Co Stable protein formulations
EP2051977A2 (fr) 2006-07-20 2009-04-29 Amgen Inc. HÉTÉROCYCLES AROMATIQUES D'AZOLE SUBSTITUÉS, UTILISÉS EN TANT QU'INHIBITEURS DE LLbeta-HSD-1
CA2682147C (fr) 2007-03-30 2017-08-08 Ambrx, Inc. Polypeptides fgf-21 modifies, et leurs utilisations
WO2008134547A1 (fr) * 2007-04-25 2008-11-06 Xenon Pharmaceuticals Inc. Procédés de traitement de maladies ou d'affections associées aux canaux sodiques au moyen de composés d'hydroxycyclohexane et d'hydroxypipéridine
WO2008153722A1 (fr) 2007-05-22 2008-12-18 The Board Of Regents Of The University Of Texas System Régulation post-translationnelle d'activités catalytiques du cytochrome p450 46a1, et utilisations associées
WO2009117421A2 (fr) 2008-03-17 2009-09-24 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
CN103508936A (zh) 2008-08-22 2014-01-15 赛诺菲-安万特 用于制备吲哚苄胺化合物的中间体
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
DE102009022896A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
JP5316468B2 (ja) 2010-04-09 2013-10-16 株式会社豊田自動織機 リアクトル構造
HUE052110T2 (hu) 2010-07-29 2021-04-28 Rigel Pharmaceuticals Inc AMPK-t aktiváló heterociklusos vegyületek és alkalmazásuk
EP2651405A2 (fr) 2010-12-14 2013-10-23 Electrophoretics Limited Inhibiteurs de caséine kinase 1 (ck1 )
US8648079B2 (en) * 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds

Also Published As

Publication number Publication date
US10550129B2 (en) 2020-02-04
US8648079B2 (en) 2014-02-11
LT2763979T (lt) 2019-03-25
US20210206781A1 (en) 2021-07-08
EA025662B1 (ru) 2017-01-30
US10144743B2 (en) 2018-12-04
NZ623185A (en) 2016-01-29
CA2851087A1 (fr) 2013-04-18
GEP201706608B (en) 2017-01-25
DOP2014000064A (es) 2014-07-15
ECSP14013329A (es) 2014-05-31
AU2012321815A8 (en) 2014-06-12
SG2014010417A (en) 2014-06-27
US20140228373A1 (en) 2014-08-14
DK2763979T3 (en) 2019-04-01
ES2716531T3 (es) 2019-06-13
US20160326136A1 (en) 2016-11-10
BR112014007257A2 (pt) 2017-03-28
US20130090341A1 (en) 2013-04-11
ME03372B (fr) 2020-01-20
US20200157117A1 (en) 2020-05-21
EP2763979A1 (fr) 2014-08-13
CY1121549T1 (el) 2020-05-29
UA115133C2 (uk) 2017-09-25
AR088226A1 (es) 2014-05-21
CR20140151A (es) 2014-05-26
US20190233436A1 (en) 2019-08-01
US10717748B2 (en) 2020-07-21
KR101967497B1 (ko) 2019-04-09
UY34365A (es) 2013-05-31
US8865717B2 (en) 2014-10-21
US9193709B2 (en) 2015-11-24
AU2012321815A1 (en) 2014-04-24
MX2014004253A (es) 2014-06-11
AU2012321815B2 (en) 2017-03-09
US11174272B2 (en) 2021-11-16
SI2763979T1 (sl) 2019-04-30
SMT201900173T1 (it) 2019-05-10
PE20141120A1 (es) 2014-09-15
US9586930B2 (en) 2017-03-07
JP2014528904A (ja) 2014-10-30
US20140088118A1 (en) 2014-03-27
MY176126A (en) 2020-07-24
US10273245B2 (en) 2019-04-30
CA2851087C (fr) 2019-09-24
EP2763979B1 (fr) 2018-12-26
ZA201402424B (en) 2015-07-29
US20170145031A1 (en) 2017-05-25
PH12014500759A1 (en) 2014-05-12
HRP20190491T1 (hr) 2019-05-03
JP6117191B2 (ja) 2017-04-19
CO6940432A2 (es) 2014-05-09
PT2763979T (pt) 2019-04-12
US20150376205A1 (en) 2015-12-31
IL231678A0 (en) 2014-05-28
PL2763979T3 (pl) 2019-06-28
TR201902788T4 (tr) 2019-03-21
TN2014000122A1 (en) 2015-07-01
EA201490747A1 (ru) 2014-08-29
US8871766B2 (en) 2014-10-28
MA35623B1 (fr) 2014-11-01
CN103842356B (zh) 2017-03-15
TWI582084B (zh) 2017-05-11
CN103842356A (zh) 2014-06-04
KR20140072902A (ko) 2014-06-13
BR112014007257B1 (pt) 2023-04-25
US9440990B2 (en) 2016-09-13
RS58470B1 (sr) 2019-04-30
TW201329068A (zh) 2013-07-16
BR122022001219B1 (pt) 2023-03-14
HUE043171T2 (hu) 2019-08-28
CL2014000806A1 (es) 2014-09-05
US20190071455A1 (en) 2019-03-07
MX360706B (es) 2018-11-14
US20140088146A1 (en) 2014-03-27
WO2013054822A1 (fr) 2013-04-18
IL231678A (en) 2017-03-30

Similar Documents

Publication Publication Date Title
ZA201402424B (en) 1- arylcarbonyl -4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
AP3544A (en) Compounds for the treatment of addiction
IL231835A0 (en) Pyrrolopyrimidine compounds for cancer treatment
ZA201403795B (en) Formulations for the treatment of diabetes
AP2014007729A0 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
EP2611765A4 (fr) Méthodes de traitement des maladies neurodégénératives
ZA201501390B (en) Compounds for the treatment of mtor pathway related diseases
PL2867218T3 (pl) Pochodne kwasu dimetylobenzoesowego użyteczne w leczeniu stanów zapalnych
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
HUP1100290A2 (en) Combination compositions for the treatment of proliferative diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
GB201106154D0 (en) Compounds for the treatment of metabolic disorders
GB201106142D0 (en) Compounds for the treatment of metabolic disorders
GB201106981D0 (en) Compounds for the treatment of clostridium difficle-associated disease
GB201101183D0 (en) Treatment of neurodegenerative disorders
HK1197236B (en) Compounds for the treatment of addiction
GB201119533D0 (en) Compounds for the treatment of neoplasia
AU2012903365A0 (en) Compounds for the treatment of mTOR pathway related diseases
IL232294B (en) Preparations for the treatment of diabetes